Nobuhiro Kado

659 total citations
20 papers, 232 citations indexed

About

Nobuhiro Kado is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Nobuhiro Kado has authored 20 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Reproductive Medicine and 6 papers in Obstetrics and Gynecology. Recurrent topics in Nobuhiro Kado's work include Endometrial and Cervical Cancer Treatments (6 papers), Ovarian cancer diagnosis and treatment (5 papers) and Cancer Genomics and Diagnostics (5 papers). Nobuhiro Kado is often cited by papers focused on Endometrial and Cervical Cancer Treatments (6 papers), Ovarian cancer diagnosis and treatment (5 papers) and Cancer Genomics and Diagnostics (5 papers). Nobuhiro Kado collaborates with scholars based in Japan, United Kingdom and United States. Nobuhiro Kado's co-authors include Yasuyuki Hirashima, Masakazu Abé, Munetaka Takekuma, Shiho Kuji, Nobutaka Takahashi, Aki Tanaka, Yoshikazu Ichikawa, Junko Murakami, Hiroyuki Matsubayashi and Kimihiko Ito and has published in prestigious journals such as BioMed Research International, Gynecologic Oncology and Cancer Epidemiology Biomarkers & Prevention.

In The Last Decade

Nobuhiro Kado

17 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nobuhiro Kado Japan	9	110	74	56	54	45	20	232
Simon Hyde Australia	9	102 0.9×	98 1.3×	14 0.3×	94 1.7×	86 1.9×	20	241
Aljoša Mandić Serbia	9	88 0.8×	66 0.9×	7 0.1×	91 1.7×	53 1.2×	59	315
John McDonald United States	8	88 0.8×	127 1.7×	11 0.2×	21 0.4×	227 5.0×	9	303
Antonio D’Amato Italy	10	24 0.2×	88 1.2×	14 0.3×	43 0.8×	71 1.6×	40	236
Juria Akasaka Japan	9	56 0.5×	201 2.7×	15 0.3×	16 0.3×	143 3.2×	23	307
Jinxin Qiu China	8	132 1.2×	25 0.3×	34 0.6×	12 0.2×	7 0.2×	11	282
Hanifi Şahin Türkiye	10	55 0.5×	204 2.8×	7 0.1×	37 0.7×	168 3.7×	41	289
Sarah Ferguson Canada	9	165 1.5×	106 1.4×	3 0.1×	36 0.7×	82 1.8×	14	299
Nabil Abdalla Poland	9	52 0.5×	128 1.7×	9 0.2×	10 0.2×	47 1.0×	21	218
Jeremy A. King United States	10	78 0.7×	78 1.1×	20 0.4×	5 0.1×	59 1.3×	17	316

Countries citing papers authored by Nobuhiro Kado

Since Specialization

Citations

This map shows the geographic impact of Nobuhiro Kado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobuhiro Kado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobuhiro Kado more than expected).

Fields of papers citing papers by Nobuhiro Kado

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nobuhiro Kado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobuhiro Kado. The network helps show where Nobuhiro Kado may publish in the future.

Co-authorship network of co-authors of Nobuhiro Kado

This figure shows the co-authorship network connecting the top 25 collaborators of Nobuhiro Kado. A scholar is included among the top collaborators of Nobuhiro Kado based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nobuhiro Kado. Nobuhiro Kado is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nishio, Shin, Tadaaki Nishikawa, Masahiko Mori, et al.. (2025). Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial. Journal of Gynecologic Oncology. 36(4). e118–e118.

Nishimura, Seiichiro, et al.. (2025). Factors affecting the implementation of cascade testing of patients with BRCA1 or BRCA2 pathogenic germline variants in Japan. Journal of Genetic Counseling. 34(3). e70055–e70055.

Nishimura, Seiichiro, Nobuhiro Kado, Yasue Horiuchi, et al.. (2024). Two Japanese families with familial pancreatic cancer with suspected pathogenic variants of CDKN2A: a case report. Hereditary Cancer in Clinical Practice. 22(1). 11–11. 3 indexed citations

Matsubayashi, Hiroyuki, Haruki Kobayashi, Koichi Mitsuya, et al.. (2023). A Japanese case of ovarian mucinous adenocarcinoma with germline double variants of MSH2 and BRCA2. Journal of Human Genetics. 68(11). 783–787. 2 indexed citations

Matsubayashi, Hiroyuki, Hirotoshi Ishiwatari, Junya Sato, et al.. (2023). A Japanese Family Meeting the Clinical Diagnostic Criteria for MEN1 with a <i>MEN1</i> Variant of Uncertain Significance. Internal Medicine. 63(8). 1119–1123. 1 indexed citations

Goto, Keisuke, Shusuke Yoshikawa, Yoshio Kiyohara, et al.. (2023). A Japanese case of familial malignant melanoma with germline CDK4 variant incidentally diagnosed by cancer genome profiling. Journal of Human Genetics. 68(5). 359–361.

Matsubayashi, Hiroyuki, Nobuhiro Kado, Seiichiro Nishimura, et al.. (2022). Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system. Japanese Journal of Clinical Oncology. 52(6). 599–608. 7 indexed citations

Matsubayashi, Hiroyuki, Akiko Todaka, Takeshi Kawakami, et al.. (2022). Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients. Journal of Human Genetics. 68(2). 81–86. 7 indexed citations

Horiuchi, Yasue, Hiroyuki Matsubayashi, Seiichiro Nishimura, et al.. (2020). Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients. Human Genetics. 140(2). 321–331. 15 indexed citations

10.

Iihara, Hirotoshi, Mototsugu Shimokawa, Yukiyoshi Fujita, et al.. (2020). Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study. Gynecologic Oncology. 156(3). 629–635. 9 indexed citations

11.

Matsubayashi, Hiroyuki, Yasue Horiuchi, Nobuhiro Kado, et al.. (2020). Role of Tumor Mutation Burden Analysis in Detecting Lynch Syndrome in Precision Medicine: Analysis of 2,501 Japanese Cancer Patients. Cancer Epidemiology Biomarkers & Prevention. 30(1). 166–174. 4 indexed citations

12.

Nishio, Shin, Koji Matsuo, Satoshi Yamaguchi, et al.. (2019). Changes in the Clinicopathological Demographics of Vulvar Cancer in Japan: Increasing Oldest-Old, Stage Shifting, and Decreasing Cohort-Level Survival †. Journal of Clinical Medicine. 8(12). 2081–2081. 11 indexed citations

13.

Matsubayashi, Hiroyuki, Yasue Horiuchi, Yasuyuki Hirashima, et al.. (2019). Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome. BMC Cancer. 19(1). 1014–1014. 5 indexed citations

14.

Takekuma, Munetaka, Nobuhiro Kado, Shiho Kuji, et al.. (2017). The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I–II cervical cancer: A review. Journal of obstetrics and gynaecology research. 43(4). 617–626. 37 indexed citations

15.

Takekuma, Munetaka, Nobuhiro Kado, Shiho Kuji, et al.. (2016). Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy. International Journal of Clinical Oncology. 21(4). 741–747. 31 indexed citations

16.

Abé, Masakazu, Yasuyuki Hirashima, Nobuhiro Kado, et al.. (2015). Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Supportive Care in Cancer. 24(2). 675–682. 54 indexed citations

17.

Takahashi, Nobutaka, Nobuhiro Kado, Shiho Kuji, et al.. (2015). Five Cases of Cervical Cancer Where Laparoscopic Ovarian Transposition Was Performed Before Pelvic Radiotherapy. Journal of Minimally Invasive Gynecology. 22(6). S203–S203. 1 indexed citations

18.

Takekuma, Munetaka, Nobuhiro Kado, Shiho Kuji, et al.. (2015). Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer. Journal of obstetrics and gynaecology research. 41(10). 1638–1643. 13 indexed citations

19.

Abé, Masakazu, Nobuhiro Kado, Shiho Kuji, et al.. (2015). Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy. BioMed Research International. 2015. 1–6. 15 indexed citations

20.

Yoshida, Takuya, Yukiko Yamamoto, H Orita, et al.. (1996). Studies on Quinolone Antibacterials. IV. Structure-Activity Relationships of Antibacterial Activity and Side Effects for 5- or 8-Substituted and 5,8-Disubstituted-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-1,4-dihydro-4-oxoquinoline-3-carboxylic Acids.. Chemical and Pharmaceutical Bulletin. 44(5). 1074–1085. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact